Clinical trial NCT03980925: Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Official title: A Phase II Study of Platinum-doublet Chemotherapy in Combination With Nivolumab as First-line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic G3 Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Neuroendocrine Tumors
Neuroendocrine Neoplasm
Gastroenteropancreatic Neuroendocrine Tumor
Lead sponsor: Grupo Espanol de Tumores Neuroendocrinos
Sponsor class: OTHER
First posted: 2019-06-10
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a prospective, multi-centre, open label, non-randomized phase II study evaluating the efficacy and safety of nivolumab plus platinum-based chemotherapy in patients with advanced G3 NENs of the GEP tract or of UK origin.


Eligibility criteria: Inclusion Criteria:

* Confirmed G3 NENs originated in the gastroenteropancreatic tract (WHO 2010 classification). Patients with a G3 NEN of unknown primary will also be eligible for this trial.
* Ki-67 \>20% or mitotic rate \> 20 per 10 High-power field (HPF).
* Metastatic or locally advanced unresectable disease not amenable to treatment with curative intent.
* No prior systemic treatment for advanced disease nor as adjuvant therapy.
* Availability of fresh or archive formalin-fixed, paraffin-embedded tumor tissue for biomarker assessment.
* Patients must have clinically and/or radiographically documented measurable disease. At least one site of disease must be unidimensionally measurable as per RECIST 1.1.
* Adequate organ function as defined by the following criteria (within 7 days prior to enrollment):

  1. absolute neutrophil count (ANC) ≥1500 cells/mm3
  2. platelets ≥100,000 cells/mm3
  3. hemoglobin ≥9.0 g/dL
  4. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x upper limit of normal (ULN); in patients with liver metastases AST and ALT ≤5.0 x ULN
  5. total bilirubin ≤1.5 x ULN
  6. serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥60 mL/min.
* Male or female, age ≥18 years.
* Eastern cooperative oncology group (ECOG) performance status of 0-2.
* Life expectancy of ≥12 weeks.
* Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to treatment initiation.
* Highly effective contraception (i.e. methods with a failure rate of less than 1 % per year) for both fertile, sexually active male and female subjects. Highly effective contraception must be used 28 days prior to first trial treatment administration, for the duration of trial treatment, and at least for 60 days after stopping trial treatment.
* Signed and dated informed consent document must be given according to international conference harmonisation (ICH)/ Good clinical practice (GCP), and national/local regulations indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrolment.

Exclusion Criteria:

* The following endocrine tumor types may not be included: paraganglioma, adrenal, thyroid parathyroid or pituitary endocrine tumors. Large or small cell lung neuroendocrine carcinoma of the lung will also be excluded.
* Prior therapy with any immune checkpoint inhibitor.
* Major surgery, except diagnostic biopsy, in \<4 weeks or radiation therapy \<2 weeks prior to starting study treatment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiated.
* Prior organ transplantation, including allogeneic stem-cell transplantation.
* Prior history of non-infectious pneumonitis requiring steroids or current pneumonitis.
* Systemic chronic steroid therapy (\> 10 mg/day prednisone or equivalent) or other immunosuppressive agents or use of any investigational drug within 28 days before the start of trial treatment. Short-term administration of steroids for allergic reactions or management of immune-related adverse events is allowed. Topical, inhaled, nasal and ophthalmic steroids are also allowed.
* Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.
* Known history of positive testing for Human Immunodeficiency Virus (HIV) infection, known history of or positive tests for Hepatitis B virus surface antigen (HBVsAg) or Hepatitis C ribonucleic acid (HCV RNA) indicating acute or chronic infection or other significant acute or chronic infections requiring medication at study entry.
* Active, known or suspected autoimmune disease or a documented history of autoimmune disease, including ulcerative colitis and Crohn's disease. (Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll).
* Active seizure disorder or evidence of brain metastases, spinal cord compression, or carcinomatous meningitis.
* A serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment will not be allowed to enter the study. Any of the following within the 12 months prior to study drug administration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, new york heart association (NYHA) class \> III congestive heart failure, cerebrovascular accident or transient ischemic attack and 6 months for deep vein thrombosis or pulmonary embolism.
* Known hypersensitivity reactions to monoclonal antibodies (≥ grade 3 according to NCI Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 \[xliii\] or any past medical history of anaphylaxis or uncontrolled asthma (i.e., 3 or more asthma characteristics partially controlled).
* Any other prior malignancy within 5 years of study entry, with the exception of adequately treated in-situ carcinoma of the cervix, breast or uteri, or non-melanomatous skin cancer.
* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
* Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.
* Female patients who are pregnant or lactating, or men and women of reproductive potential not willing or not able to employ an effective method of birth control/contraception to prevent pregnancy during treatment and for 6 months after discontinuing study treatment The definition of effective contraception should be in agreement with local regulation and based on the judgment of the principal investigator or a designated associate.
* Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for study entry.

Primary outcomes:
measure: Overall Survival Rate at 12 Months
timeFrame: 12 months
Secondary outcomes:
measure: Overall Response Rate (ORR)
timeFrame: Throughout the study period, approximately 24 months
measure: Progression-free Survival (PFS) Rate
timeFrame: Throughout the study period, approximately 24 months
measure: Median Overall Survival
timeFrame: 30 months
measure: Predictive Biomarkers
timeFrame: 30 months
measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
timeFrame: 30 months
measure: Median Progression-free Survival
timeFrame: 30 months
measure: Duration of Response
timeFrame: 30 months
Other outcomes:
Locations:
city: Badalona
country: Spain
facility: Institut Català d'Oncologia Badalona
state: Barcelona
city: Hospitalet de Llobregat
country: Spain
facility: Institut Català d'Oncologia l'Hospitalet
state: Barcelona
city: Barcelona
country: Spain
facility: Vall d'Hebron University Hospital
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
city: Madrid
country: Spain
facility: Hospital Universitario Ramón y Cajal
city: Madrid
country: Spain
facility: MD Anderson Cancer Madrid
city: Málaga
country: Spain
facility: Hospital Clínico Universitario Virgen de la Victoria
city: Oviedo
country: Spain
facility: Hospital Universitario Central de Asturias
city: Santander
country: Spain
facility: Hospital Universitario Marqués de Valdecilla
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocío
city: Zaragoza
country: Spain
facility: Hospital Universitario Miguel Servet
Study officials:
affiliation: Hospital Universitario 12 de Octubre
name: Rocío García-Carbonero, MD, PhD
role: STUDY_CHAIR
affiliation: Hospital Universitario 12 de Octubre
name: Maria del Carmen Riesco-Martínez, MD, PhD
role: STUDY_CHAIR
References: